Literature DB >> 7929271

Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.

A Nykjaer1, L Kjøller, R L Cohen, D A Lawrence, B A Garni-Wagner, R F Todd, A J van Zonneveld, J Gliemann, P A Andreasen.   

Abstract

The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP) binds several ligands, including complex between the two chain urokinase-type plasminogen activator (uPA) and type-1 plasminogen activator inhibitor (PAI-1), and the single chain zymogen pro-urokinase (pro-uPA). We have used truncated variants of uPA and PAI-1 as well as Fab fragments of monoclonal antibodies with known epitopes to identify regions in the uPA.PAI-1 complex and in pro-uPA involved in binding to alpha 2MR/LRP.uPA.PAI-1 complex bound with high affinity (EC50 about 0.4 nM) via contacts in the PAI-1 moiety as well as the uPA serine proteinase domain and the uPAA chain. Pro-uPA bound with lower affinity (EC50 about 10 nM), and efficient binding to alpha 2MR/LRP was dependent on contact with both the A chain and the serine proteinase domain. We analyzed the effect of complex formation with the urokinase receptor since this is the primary target for binding of uPA.PAI-1 and pro-uPA at the cell surface, and since it has been demonstrated that urokinase receptor-bound uPA.PAI-1 complex is internalized following interaction with alpha 2 MR/LRP (Nykjaer, A., Petersen, C. M., Møller, B., Jensen, P.H., Moestrup, S.K., Holtet, T.L., Etzerodt M., Thøgersen, H.C., Munch, M., Andreasen, P.A., and Gliemann, J. (1992) J. Biol. Chem. 267, 14543-14546). Soluble recombinant urokinase receptor blocked the binding of pro-uPA to alpha 2MR/LRP but caused only a slight reduction in the affinity for binding of uPA.PAI-1. Moreover, pro-uPA bound to the urokinase receptor at the cell surface was not internalized and degraded unless activated to uPA and complexed with PAI-1. We conclude that pro-uPA is protected against degradation via alpha 2MR/LRP when bound to uPAR due to shielding of a binding contact in the A chain, whereas the affinity of uPAR-bound uPA.PAI-1 complex for binding to alpha 2MR/LRP remains sufficient to allow rapid internalization and degradation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929271

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

2.  Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1.

Authors:  Jan K Jensen; Klavs Dolmer; Peter G W Gettins
Journal:  J Biol Chem       Date:  2009-05-13       Impact factor: 5.157

3.  Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner.

Authors:  Guangyao Yu; Ann H Rux; Peihong Ma; Khalil Bdeir; Bruce S Sachais
Journal:  Blood       Date:  2004-12-09       Impact factor: 22.113

4.  Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction.

Authors:  A Nykjaer; E I Christensen; H Vorum; H Hager; C M Petersen; H Røigaard; H Y Min; F Vilhardt; L B Møller; S Kornfeld; J Gliemann
Journal:  J Cell Biol       Date:  1998-05-04       Impact factor: 10.539

5.  Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.

Authors:  O M Andersen; H H Petersen; C Jacobsen; S K Moestrup; M Etzerodt; P A Andreasen; H C Thøgersen
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

Review 6.  Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  Biochem J       Date:  2016-08-01       Impact factor: 3.857

7.  Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.

Authors:  A Poliakov; V Tkachuk; T Ovchinnikova; N Potapenko; S Bagryantsev; V Stepanova
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

8.  The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.

Authors:  Maithili Sashindranath; Eunice Sales; Maria Daglas; Roxann Freeman; Andre L Samson; Elisa J Cops; Simone Beckham; Adam Galle; Catriona McLean; Cristina Morganti-Kossmann; Jeffrey V Rosenfeld; Rime Madani; Jean-Dominique Vassalli; Enming J Su; Daniel A Lawrence; Robert L Medcalf
Journal:  Brain       Date:  2012-07-20       Impact factor: 13.501

9.  K Domain CR9 of Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) Is Critical for Aggregated LDL-induced Foam Cell Formation from Human Vascular Smooth Muscle Cells.

Authors:  Paula Costales; Pablo Fuentes-Prior; Jose Castellano; Elena Revuelta-Lopez; Maria Ángeles Corral-Rodríguez; Laura Nasarre; Lina Badimon; Vicenta Llorente-Cortes
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

10.  The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand.

Authors:  Jørgen Gliemann; Guido Hermey; Anders Nykjaer; Claus M Petersen; Christian Jacobsen; Peter A Andreasen
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.